Bio-Rad Laboratories Inc. - Ordinary Shares - Class A Forecast, price target & analysts
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A Target price 2025 - Analyst rating & recommendation
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A Classifications & Recommendation:
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A Price Target
| Target Price | $361.67 |
| Price | $245.52 |
| Potential |
47.31%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Bio-Rad Laboratories Inc. - Ordinary Shares - Class A 2026 .
The average Bio-Rad Laboratories Inc. - Ordinary Shares - Class A target price is $361.67.
This is
47.31%
register free of charge
$430.00
75.14%
register free of charge
$285.00
16.08%
register free of charge
|
|
| A rating was issued by 9 analysts: 6 Analysts recommend Bio-Rad Laboratories Inc. - Ordinary Shares - Class A to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Bio-Rad Laboratories Inc. - Ordinary Shares - Class A stock has an average upside potential 2026 of
47.31%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.57 | 2.55 |
| 3.92% | 0.59% | |
| EBITDA Margin | 19.63% | 18.16% |
| 9.00% | 7.49% |
6 Analysts have issued a sales forecast Bio-Rad Laboratories Inc. - Ordinary Shares - Class A 2025 . The average Bio-Rad Laboratories Inc. - Ordinary Shares - Class A sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Bio-Rad Laboratories Inc. - Ordinary Shares - Class A EBITDA forecast 2025. The average Bio-Rad Laboratories Inc. - Ordinary Shares - Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| EV/Sales | 2.58 |
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A...
Current Bio-Rad Laboratories Inc. - Ordinary Shares - Class A Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Feb 12 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jan 14 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 09 2024 |
| Citigroup |
Locked
➜
Locked
|
Locked | Oct 31 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Oct 31 2024 |
| Citigroup |
Locked
➜
Locked
|
Locked | Oct 01 2024 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 27 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Feb 12 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jan 14 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 09 2024 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Oct 31 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Oct 31 2024 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Oct 01 2024 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 27 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
